Bevacizumab takes a fundamentally different approach to fighting cancer than most of the biologics in our catalogue — rather than targeting the cancer cells themselves, it targets VEGF, the signaling protein tumors rely on to grow the new blood vessels that feed them. Cut off that blood supply and tumor growth slows significantly, which is why Bevacizumab has earned approval across an unusually broad range of cancer types and remains one of the highest-volume products we export, both for its multi-indication versatility and its comparatively accessible cost-per-cycle relative to newer targeted biologics.

• Approved indications: Metastatic colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, cervical cancer, epithelial ovarian cancer, and glioblastoma
• Mechanism: Binds and neutralizes VEGF-A, blocking the angiogenesis (new blood vessel formation) tumors depend on for growth and spread
• Combination therapy: Almost always given alongside standard chemotherapy regimens specific to each cancer type, rather than as monotherapy
• Cost positioning: Notably lower cost-per-treatment-cycle than many newer-generation targeted biologics, a factor directly contributing to its consistently high export volume across our LATAM and Africa corridors

Bevacizumab's blood-vessel-blocking mechanism, while effective against tumors, also means it interferes with the body's normal wound-healing and clotting processes — which is the single most operationally important precaution for any hospital or surgical team to plan around.

• Surgical timing (critical): Must be discontinued a minimum of 28 days before any elective surgery, and not restarted until at least 28 days after, due to significantly elevated bleeding and wound-dehiscence risk
• Age restriction: Not established for use in patients under 18
• Cardiovascular monitoring: Regular blood pressure checks required — hypertension is a common and sometimes dose-limiting side effect
• Renal monitoring: Proteinuria (protein in urine) monitored regularly as a marker of kidney impact
• Contraception requirement: Required during treatment and for a minimum of 6 months following the final dose
• Rare but serious risks: Gastrointestinal perforation and thromboembolic events, both requiring immediate discontinuation if suspected

Stock status: Bulk export stock available across standard lead times

• Logistics: GDP-compliant cold-chain export (2–8°C, protected from light and agitation)
• Coverage: LATAM, Africa, GCC, Southeast Asia — among our most consistently active export corridors for this product given its broad multi-cancer approval base
• Handling note: Requires gentle handling throughout transit — the product must not be shaken, which factors into our packaging and courier protocols
• Tracking: Full shipment tracking with cold-chain verification available

What is Bevacizumab used for?

Treats metastatic colorectal, lung, kidney, cervical, ovarian, and brain cancers by blocking the tumor's blood supply.

Get Bevacizumab price from a GMP-compliant Indian supplier — how?

Send strength and destination country for a quote, factoring in any planned surgical timing.

Is surgery safe during treatment?

No — a minimum 28-day gap before and after any surgery is required due to bleeding and wound-healing risk.

Can it be used in pregnancy?

No, it may harm the unborn baby, and it isn't recommended during pregnancy.

Who exports Bevacizumab from India?

WHO-GMP certified supplier with full documentation and cold-chain logistics.